StockGuide AI
Track Stocks
EN RU ES
Centessa Pharmaceuticals

Centessa Pharmaceuticals

Price: 39.69

Company and Business Model

Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. Its core products include a pipeline of drug candidates targeting various diseases, primarily in oncology and rare diseases. The company operates through multiple business segments, emphasizing research and development to advance its therapeutic offerings. Major revenue sources are expected to stem from future product launches and collaborations with other pharmaceutical entities.

Investment Profile

The investment profile of Centessa Pharmaceuticals is more aligned with growth investors, given its focus on developing new therapies and the potential for future revenue generation. However, the high risk associated with its clinical-stage status may deter conservative investors. The stock may appeal to those with a longer investment horizon, as the company seeks to establish its market presence.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $
-1.78 Risk
EPS surprise
-36.8% worse than expected
20d volatility
0.2% stable
FMP / FinFeed data updated: 2026-06-11
Reco: Sell Potential: 40 Risk: 69 Updated: 2026-06-11 05:16
How recommendation works
Why AI thinks so:
Weak fundamentals and high risk limit upside potential.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
AI recommendation changes
Date Before After Reason
2026-06-09 02:36 Hold Sell Weak fundamentals and high risk limit upside potential.
2026-06-01 02:34 Sell Hold Weak fundamentals and high volatility signal caution.
2026-05-16 02:53 Hold Sell Weak fundamentals and high volatility raise concerns.
Analyst forecasts
Date Analyst Action Target Price Then
2026-04-20 09:12 Wells Fargo Rating Downgraded — → 42 39.66
2026-02-23 21:07 Wolfe Research Update — → 40 25.49
2026-01-29 14:25 Truist Financial Target Raised 33 → 38 24.73